What Fueled The Previous Growth In The Menopausal Hot Flashes Market?
The menopausal hot flashes market has seen considerable growth due to a variety of factors.
•The market for menopausal hot flashes has witnessed vigorous growth in the previous years. The market is predicted to expand from $15.08 billion in 2024 to $15.98 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%.
The substantial growth during the historical phase can be associated with hormone replacement therapy, inadequate treatment alternatives, heightened awareness and education, lifestyle management changes, and alternative therapies.
What Is The Expected Growth In The Menopausal Hot Flashes Market Size?
The menopausal hot flashes market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for menopausal hot flashes is predicted to witness robust expansion in the upcoming years, reaching a value of $20.37 billion in 2029 with a 6.3% compound annual growth rate (CAGR).
The anticipated market surge during the forecast period can be credited to the developments in non-hormonal treatment methods, personalized therapy strategies, attention towards natural cures, and research on neurotransmitter pathways. Significant trends projected during the forecast duration encompass non-pharmacological treatments, digital health advancements, innovative drug formulations, precision medicine in menopause, and combination therapies.
What Are The Leading Drivers Of Growth In The Menopausal Hot Flashes Market?
Government efforts targeting women's health during menopause are anticipated to fuel the menopausal hot flashes market's expansion. These initiatives focus on funding innovative research aimed at comprehending the menopausal transition, preventing sickness, and supporting studies into associated pharmacological, clinical, and epidemiological aspects, as well as preventative research. Such initiatives typically address a broad set of issues, including menopause health, managing symptoms such as hot flashes, and advocating for health through risk factor research, prevention, and early diagnosis of major health problems. For example, in January 2023, the Australian New South Wales Government agency reported that the government had committed $40.3 million over four years (2022-2023 to 2025-2026) towards establishing up to 16 new programs for women grappling with severe menopausal symptoms. Hence, government efforts related to women's health in menopause are a significant driving factor for the growth of the menopausal hot flashes market.
How Are The Segments Defined Within The Global Menopausal Hot Flashes Market?
The menopausal hot flashes market covered in this report is segmented –
1) By Type: Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment
2) By Pipeline Analysis: Phase III Drugs, Phase I And II Drugs
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospital Pharmacies
4) By Application: 51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman
Subsegments:
1) By Hormonal Treatment: Estrogen Therapy, Combined Hormonal Therapy
2) By Non-Hormonal Treatment: Selective Serotonin Reuptake Inhibitors, Gabapentinoids, Clonidine
3) By Alternative Treatment: Herbal Supplements, Acupuncture, Lifestyle Modifications
Pre-Book The Menopausal Hot Flashes Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Menopausal Hot Flashes Market?
The emergence of product innovations stands out as a notable trend in the menopausal hot flashes market. Key players in the sector are rolling out novel products to consolidate their market presence. For example, in May 2023, Astellas Pharma US Inc., an American pharmaceutical firm, announced that the Food and Drug Administration, a Federal agency in the US, sanctioned Veozah, a new treatment for hot flashes triggered by menopause. This product is the first-of-its-kind neurokinin 3 (NK3) receptor inhibitor to receive licensure for alleviating mild to severe hot flashes linked with menopause. It works by latching onto and stimulating the NK3 receptor, which plays a role in how the brain controls body temperature.
Who Are the Key Players in the Menopausal Hot Flashes Market?
Major companies operating in the menopausal hot flashes market include:
• Pfizer Inc.
• Johnson & Johnson
• The Procter & Gamble Company
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• AstraZeneca plc
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Shionogi & Co. Ltd.
• Gedeon Richter Plc
• Lupin Limited
• Hisamitsu Pharmaceutical Co. Inc.
• Noven Pharmaceuticals Inc.
• Ligand Pharmaceuticals Inc.
• Mithra Pharmaceuticals SA
• TherapeuticsMD Inc.
• Theramex Ltd.
• Ascend Therapeutics Inc.
• EndoCeutics Inc.
• Sermonix Pharmaceuticals LLC
• Ralington pharma LLP
What Is The Most Dominant Region In The Menopausal Hot Flashes Market?
North America was the largest region in the Menopausal Hot Flashes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
